Skip to content

Feasibility of Using a Structured Daily Diary

Feasibility of Using a Structured Daily Diary to Assess Mood, Stressful Events, Support, Substance Use, and Sexual Behavior in HIV-Positive Young Men Who Have Sex With Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01953653
Enrollment
67
Registered
2013-10-01
Start date
2013-02-28
Completion date
2014-02-28
Last updated
2017-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infection

Brief summary

This protocol explores the feasibility and acceptability of using two daily diary methods to analyze state-dependent variables and psychosocial health outcomes in Human Immunodeficiency Virus (HIV)-positive young men who have sex with men (YMSM). The study will explore the potential of diaries for use in feedback-based interventions.

Interventions

BEHAVIORALStructured daily diary

The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.

Sponsors

University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
16 Years to 24 Years
Healthy volunteers
No

Inclusion criteria

* Receives services at one of the selected Adolescent Medicine Trial Unit (AMTU) sites; * HIV-1 infection as documented in the participant's medical record by at least one of the following criteria: * Reactive HIV screening test result with an antibody-based, Food and Drug Administration (FDA)-licensed assay followed by a positive supplemental assay (e.g., HIV-1 Western Blot, HIV-1 indirect immunofluorescence); * Positive HIV-1 deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) assay; * Plasma HIV-1 quantitative ribonucleic acid (RNA) assay \>1,000 copies/mL; or * Positive plasma HIV-1 RNA qualitative assay * Between the ages of 16-24 years, inclusive, at the time of screening; * Born biologically male and self-identifies as male at the time of screening; * HIV-infected through sexual behavior; * At least one self-reported sexual encounter with another man involving oral or anal sex in the past 12 months prior to screening; * At least one self-reported episode of unprotected vaginal or anal intercourse within the past 90 days prior to screening and/or substance use, defined as at least one occasion in which four or more alcoholic beverages were consumed and/or two or more occasions of illicit drug use, in the past 90 days, as assessed by the Assessment of Substance Use and Sexual Behavior questionnaire (CRF (F107)); * Has active cell phone service; is able to access his cell phone seven days a week between 6:00 PM and 6:00 AM the next morning; and is willing and able to use approximately 10 minutes of talk time and receive two text messages per day; * Consistent internet access seven days a week between 6:00 PM and 6:00 AM the next morning; * Ability to understand, read, and speak English; * Ability to read at a fifth grade level, as assessed by the Rapid Estimate of Adolescent Literacy in Medicine (REALM)-TEEN; and * Willingness to provide signed informed consent for study participation.

Exclusion criteria

* HIV infected via modes other than sexual behavior (e.g., perinatally, via shared needles, or blood transfusion, etc.); * Previously enrolled in Adolescent Trials Network (ATN) 112; * Active psychiatric condition that in the opinion of the site Principal Investigator (PI) or designee would interfere with the ability to give true informed consent and to adhere to the study requirements; * Visibly distraught and/or visibly emotionally unstable (e.g., exhibiting suicidal, homicidal, impulsive or violent behavior); * Active drug or alcohol use or dependence that, in the opinion of the site personnel, would interfere with the ability to give true informed consent and to adhere to the study requirements; * Acute illness that, in the opinion of the treating clinician, would interfere with the participant's ability to adhere to the protocol requirements and/or interfere with the protocol objectives.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants who Complete the 66-Day Structured Daily Diary66 daysThe first primary objective of this study is to implement a 66-day structured daily diary with 90 HIV-positive YMSM to explore relationships among daily mood, stressful events, social support, substance use, sexual behavior, and adherence to ART among youth who are currently prescribed to take medication.
Rate of Completion of 66-Day Structured Daily Diary by Modality Type66 daysThe second primary objective is to explore the feasibility and acceptability of using two daily diary modalities (IVR and IWR) as (1) a novel method of data collection in research involving HIV-positive YMSM, and (2) a potential tool to provide personalized feedback and/or assist with self-monitoring among HIV-positive YMSM.
Reasons and Rate of for Non-completion of 66-Day Structured Daily Diary66 daysThe second primary objective is to explore the feasibility and acceptability of using two daily diary modalities (IVR and IWR) as (1) a novel method of data collection in research involving HIV-positive YMSM, and (2) a potential tool to provide personalized feedback and/or assist with self-monitoring among HIV-positive YMSM.

Secondary

MeasureTime frameDescription
Participant Responses to how Diary can Provide Personalized Feedback on Triggers to Risk Behaviors66 daysThe secondary objective of this study is to obtain feedback from HIV-positive YMSM on how the diary could be used to provide personalized feedback on triggers to risk behaviors, such as substance use, unprotected sexual behavior, and poor medication adherence. These data will be obtained through debriefing interviews.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026